What Base4 Biotechnology does

Base4 Biotechnology is a privately held, Durham, North Carolina-based biotechnology company (founded 2009 as Nymirum, rebranded in 2024) developing RNA-targeted small molecule therapeutics for diseases that have historically been difficult to drug. The company is headquartered in Durham with 11-50 employees and operates as a pre-commercial drug discovery platform rather than a clinical-stage asset company. Its end users are patients with neurodegenerative, neuromuscular, oncological, cardiovascular, immunological, and rare diseases; its direct customers are pharmaceutical partners pursuing co-development and licensing arrangements.

The company's core offering is the VERITAS Platform (Validated Ensembles of RNA Interactions and Targeted AI-enabled Small Molecules), an AI-enhanced, quantum biophysical discovery engine built around its DART (Dynamic Atomic-scale RNA Targets) technology suite. DART leverages powerful NMR observables, machine learning, computational tools, and an internal proprietary database to experimentally determine atomic-resolution ensembles of druggable RNA conformations — not computational models, but experimentally validated structures. VERITAS layers generative AI and combinatorial methods on top of DART to perform multi-billion-scale virtual compound screens in days, identify novel chemotypes, and guide hit-to-lead and lead optimization with atomic-level pocket visibility. The platform claims over 100x enrichment versus conventional screening approaches and is positioned as mechanism-agnostic across microRNAs, mRNA, pre-mRNAs, and repeat expansion RNA.

Base4's business model is enterprise pharma partnering and licensing rather than direct product commercialization. The company runs internal discovery programs while actively seeking strategic collaborations with pharma groups for co-development, generating revenue through licensing and royalty arrangements. Disclosed equity funding totals only ~$3.89M across two early rounds (2009 and 2010), with Hopen Life Science Ventures and Orchard Venture Partners among the named investors; no public funding rounds, named pharma partners, or revenue figures have been disclosed. Co-founders include Dr. Hashim Al-Hashimi (NAS Award in Molecular Biology, 2020), CEO Joshua Fairbank (co-founder of NASDAQ-listed Akebia and Aerpio), and Michael Pape (co-founder of Esperion, sold to Pfizer for $1.3B, and a veteran of Lipitor R&D at Upjohn, Parke-Davis, and Pfizer).

Name

Base4 Biotechnology

Legal name

Base4 Biotechnology Inc

Website

https://base4.bio

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Base4 Biotechnology is a privately held, Durham-based biotech that uses its AI-enhanced VERITAS Platform and DART technology to discover RNA-targeted small molecule therapeutics. It serves pharmaceutical partners through co-development and licensing deals, targeting neurodegenerative, neuromuscular, oncology, cardiovascular, immunological, and rare diseases.

Ownership category

akta.pro rank

Product category

RNA-targeted Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

Keywords

• RNA-targeted drug discovery
• Small molecule therapeutics
• Structure-based drug design
• AI-enhanced drug screening
• Quantum biophysical platform

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Partnerships and Licensing: Revenue generated through strategic collaborations with pharma companies for co-development of RNA-targeting therapeutics. The company is developing internal programs while engaging with like-minded pharma groups to accelerate medicine development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Base4 Biotechnology develops RNA-targeted small molecule therapeutics through its proprietary VERITAS Platform, an AI-enhanced quantum biophysical discovery engine. The platform experimentally resolves dynamic atomic-resolution RNA structures using NMR, ML, and GenAI, then performs multi-billion-scale compound screening to identify selective small molecule modulators. The company combines internal drug discovery programs with strategic pharma co-development partnerships to address neurodegenerative, neuromuscular, oncology, cardiovascular, immunology, and rare diseases.

Product overview

Base4 Biotechnology operates as a unified discovery platform built around its VERITAS Platform, which integrates the DART (Dynamic Atomic-scale RNA Targets) technology as its core structural determination engine. VERITAS serves as the AI-enhanced screening and optimization layer, while DART provides the atomic-resolution RNA conformational data that enables structure-based drug discovery. The company applies this integrated platform to develop RNA-targeting small molecule therapeutics across multiple disease areas including oncology, neurology, neuromuscular, cardiovascular, immunology, and rare diseases.

Differentiator

Problem solved

Functional benefit

Brands

• VERITAS Platform: AI-enhanced, quantum biophysical discovery platform that resolves dynamic atomic-resolution structures of RNA targets and screens for selective molecules against druggable RNA regions.
• DART Platform

Products and services

• VERITAS Platform

Quantifiable outcome

• Over 2 orders of magnitude (100x) enrichment of hits versus conventional screens

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Arrakis Therapeutics: Arrakis is a direct competitor developing RNA-targeted small molecule therapeutics. Both companies pursue structure-based discovery of selective binders against RNA targets via proprietary platforms, targeting similar disease areas and competing for the same pharma partnership capital.
• Ribometrix: Ribometrix discovers small molecule drugs that modulate RNA structure and function, including splicing and translation control. It overlaps directly with Base4's VERITAS platform in mechanism and target class, pursuing pharma partnerships for pipeline advancement.
• Skyhawk Therapeutics: Skyhawk uses its SkySTAR platform to discover small molecules that modify RNA splicing, with major pharma partnerships (e.g., Vertex, Merck). It is a well-capitalized direct peer in RNA-targeted small molecule discovery with a partnership-driven business model like Base4's.
• Expansion Therapeutics: Expansion Therapeutics focuses on small molecule therapeutics for repeat expansion diseases, an explicit focus area cited by Base4 (repeat expansion RNA). Both companies apply structure-informed design to RNA targets in neurological and rare diseases.
• Remix Therapeutics: Remix is developing small molecules that modulate RNA processing, including splicing, with a data-driven discovery engine. It overlaps with Base4's platform in targeting RNA processing mechanisms and pursuing oncology and rare disease indications.
• Accent Therapeutics: Accent develops small molecule therapies targeting RNA-modifying proteins (e.g., METTL3). It is a direct peer in RNA-targeted small molecule drug discovery with overlapping oncology focus and a similar partnership-driven model.

Emerging players

• Atomic AI: Atomic AI uses AI and structural biology to predict RNA 3D structures and identify small molecule binders, paralleling Base4's AI-enhanced, structure-based approach. It represents an emerging competitor combining deep learning with RNA structural resolution.
• Shape Therapeutics: Shape Therapeutics is an RNA-focused platform company combining RNA biology, structural biology, and AI/ML across modalities. It is an emerging player with thematic overlap to Base4's AI/RNA platform thesis, though broader in modality scope.

Broad incumbents

• Denali Therapeutics: Denali is a larger, publicly traded biotech developing therapeutics for neurodegenerative and rare diseases — a primary focus area for Base4. It operates more broadly with multiple modalities, including small molecules and biologics, serving as a comparable end-market incumbent.

Others

• Prelude Therapeutics: Prelude is a clinical-stage precision oncology company using a discovery engine to develop small molecule therapies. It shares a structure-based small molecule discovery philosophy and pharma partnership orientation with Base4, though it is in a more advanced development stage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/nymirum

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Base4 Biotechnology